{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:29:46Z","timestamp":1790958586058,"version":"4.1.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ctrv.2023.102510","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T03:43:09Z","timestamp":1672890189000},"page":"102510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies"],"prefix":"10.1016","volume":"113","author":[{"given":"Elizabeth","family":"Smyth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2023.102510_b0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3324\/haematol.2012.081885","article-title":"Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands","volume":"99","author":"van de Schans","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2023.102510_b0010","unstructured":"Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). EER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD. https:\/\/seer.cancer.gov\/csr\/1975_2017\/, Based on November 2019 SEER data submission, posted to the SEER web site, April 2020."},{"key":"10.1016\/j.ctrv.2023.102510_b0015","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0020","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102510_b0025","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102510_b0035","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0040","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102510_b0045","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2023.102510_b0050","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG","volume":"133","author":"Brady","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0055","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03","volume":"36","author":"MacManus","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0060","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0065","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>\u2020<\/sup><sup>\u2606<\/sup>","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0070","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1\u20132 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0075","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0080","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group","volume":"178","author":"Alonso-\u00c1lvarez","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2023.102510_b0085","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2023.102510_b0095","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.2020006784","article-title":"Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma","volume":"138","author":"Xu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0100","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"B\u00f6d\u00f6r","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-022-01295-3","article-title":"Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination","volume":"15","author":"Lew","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0110","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle Cell Lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0115","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0120","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0125","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2023.102510_b0130","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0135","first-page":"1531","article-title":"Combination of Lenalidomide and Rituximab (R2) Targets Immune Dysfunction in FL By Activating T and NK Cells Ex Vivo and Is Differentiated from Chemotherapy","volume":"130","author":"Chiu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0140","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102510_b0145","doi-asserted-by":"crossref","first-page":"e1409322","DOI":"10.1080\/2162402X.2017.1409322","article-title":"NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment","volume":"7","author":"Vo","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2023.102510_b0150","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.2147\/DDDT.S281614","article-title":"An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date","volume":"15","author":"Yilmaz","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ctrv.2023.102510_b0155","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"NEJM"},{"key":"10.1016\/j.ctrv.2023.102510_b0160","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0165","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.7513","article-title":"MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Andorsky","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0170","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-145640","article-title":"Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma","volume":"138","author":"Lansigan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0175","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft ModelsComparison of GA101, Rituximab, and Ofatumumab","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2023.102510_b0180","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell\u2013mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0185","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"NEJM"},{"key":"10.1016\/j.ctrv.2023.102510_b0190","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41408-021-00539-8","article-title":"Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed\/refractory follicular lymphoma: final analysis of a Phase Ib\/II trial","volume":"11","author":"Morschhauser","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2023.102510_b0195","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood.2021013526","article-title":"Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study","volume":"139","author":"Bachy","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0200","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102510_b0205","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7524","article-title":"Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): Update from phase 1\/2 trial","volume":"40","author":"Falchi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0210","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/j.clml.2021.12.010","article-title":"Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed\/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study","volume":"22","author":"Palomba","year":"2022","journal-title":"Clinl Lymphoma Myeloma and Leuk"},{"key":"10.1016\/j.ctrv.2023.102510_b0215","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2023.102510_b0220","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-019-0814-6","article-title":"EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0225","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2217\/fon-2020-1244","article-title":"EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed\/refractory follicular lymphoma","volume":"17","author":"Julia","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0230","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"B\u00e9guelin","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2023.102510_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.04.004","article-title":"Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response","volume":"37","author":"B\u00e9guelin","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2023.102510_b0240","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nm.4092","article-title":"An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation","volume":"22","author":"Souroullas","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2023.102510_b0245","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/bloodadvances.2020002773","article-title":"Treating lymphoma is now a bit EZ-er","volume":"5","author":"Morin","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2023.102510_b0250","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0255","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7572","article-title":"Updated interim analysis of the randomized phase 1b\/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed\/refractory follicular lymphoma","volume":"40","author":"Batlevi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0260","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2023.102510_b0265","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"NEJM"},{"key":"10.1016\/j.ctrv.2023.102510_b0270","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab-and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2023.102510_b0275","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0280","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am J Haematol"},{"key":"10.1016\/j.ctrv.2023.102510_b0285","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a Dual PI3K\u03b4\/CK1\u03b5 Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0290","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(22)00200-5","article-title":"The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0295","unstructured":"Gilead Sciences: Important drug warning: decreased overall survival and increased risk of serious infections in patients receiving Zydelig (idelalisib). , March, 2016."},{"key":"10.1016\/j.ctrv.2023.102510_b0300","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0305","unstructured":"FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib). News release. FDA. June 30, 2022. https:\/\/bit.ly\/3OUyTDh."},{"key":"10.1016\/j.ctrv.2023.102510_b0310","doi-asserted-by":"crossref","unstructured":"Gribben JG JW, Jacobs RW, et al. : Umbralisib plus ublituximab (U2) is superior to obinutuzumab plus chlorambucil (O+Chl) in patients with treatment na\u00efve (TN) and relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): results from the phase 3 Unity-CLL study. . 62nd ASH meeting, 2020. Abstract 543. https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper134783.html.","DOI":"10.1182\/blood-2020-134783"},{"key":"10.1016\/j.ctrv.2023.102510_b0315","unstructured":"FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib). FDA Feb 3, 2022. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-investigating-possible-increased-risk-death-lymphoma-medicine-ukoniq- umbralisib (accessed Feb 14, 2022)."},{"key":"10.1016\/j.ctrv.2023.102510_b0320","unstructured":"Press release: TG Therapeutics provides regulatory update. Nov 30, 2021. https:\/\/ir.tgtherapeutics.com\/news-releases\/news-release- details\/tg-therapeutics-provides-regulatory-update (accessed March 7, 2022)."},{"key":"10.1016\/j.ctrv.2023.102510_b0325","unstructured":"MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting 2022."},{"key":"10.1016\/j.ctrv.2023.102510_b0330","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2023.102510_b0335","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0340","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2023.102510_b0345","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as Treatment for Patients With Relapsed\/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study","volume":"36","author":"Gopal","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0350","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102510_b0355","doi-asserted-by":"crossref","unstructured":"Roberts AW: Therapeutic development and current uses of BCL-2 inhibition. Hematology 2014, the American Society of Hematology Education Program Book 2020:1-9, 2020.","DOI":"10.1182\/hematology.2020000154"},{"key":"10.1016\/j.ctrv.2023.102510_b0360","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non\u2013hodgkin lymphoma treated with Venetoclax in a phase I, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Can Res"},{"key":"10.1016\/j.ctrv.2023.102510_b0365","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0370","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-145217","article-title":"Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403)","volume":"138","author":"Portell","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0375","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/bloodadvances.2021006520","article-title":"SAKK 35\/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma","volume":"6","author":"Stathis","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2023.102510_b0380","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.7534","article-title":"Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL): Primary analysis of a phase 1b\/2 trial","volume":"39","author":"Bannerji","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100832","article-title":"Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas","volume":"50","author":"Bednarska","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.ctrv.2023.102510_b0390","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0395","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/bloodadvances.2021006240","article-title":"Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma","volume":"6","author":"Nastoupil","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2023.102510_b0400","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.7560","article-title":"Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study","volume":"39","author":"Hawkes","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01097-z","article-title":"Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress","volume":"14","author":"Chu","year":"2021","journal-title":"Journal of Hematol Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0410","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1016\/S2352-3026(21)00311-2","article-title":"Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: A cohort of a multicentre, single-arm, phase 1b\/2 study","volume":"8","author":"Diefenbach","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ctrv.2023.102510_b0415","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0420","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1158\/1078-0432.CCR-15-2488","article-title":"Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed\/Refractory CD22+ B-cell Non-Hodgkin Lymphoma","volume":"22","author":"Ogura","year":"2016","journal-title":"Clinical Can Res"},{"key":"10.1016\/j.ctrv.2023.102510_b0425","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","article-title":"Bispecific, T-cell-recruiting antibodies in B-cell malignancies","volume":"11","author":"Lejeune","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2023.102510_b0430","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ctrv.2023.102510_b0435","volume":"39","author":"Jacobson","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0440","unstructured":"Reid R, Friedberg JW: Management of marginal zone lymphoma. Oncology (Williston Park) 27:840, 842, 844, 2013."},{"key":"10.1016\/j.ctrv.2023.102510_b0445","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.beha.2016.07.002","article-title":"Epidemiology and environmental aspects of marginal zone lymphomas","volume":"30","author":"Sriskandarajah","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.ctrv.2023.102510_b0450","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0455","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0460","article-title":"Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","volume":"6","author":"Saifi","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0465","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2023.102510_b0470","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejca.2021.05.004","article-title":"Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02\/ALLG NHL15","volume":"152","author":"MacManus","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2023.102510_b0475","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","article-title":"Optimizing therapy for nodal marginal zone lymphoma","volume":"127","author":"Thieblemont","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0480","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.beha.2016.11.001","article-title":"Pathology of nodal marginal zone lymphomas","volume":"30","author":"Pileri","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.ctrv.2023.102510_b0485","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00277-011-1337-6","article-title":"Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study","volume":"91","author":"Kang","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2023.102510_b0490","article-title":"The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma","author":"Laribi","year":"2016","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0495","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102510_b0500","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2023.102510_b0505","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"PNAS"},{"key":"10.1016\/j.ctrv.2023.102510_b0510","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0515","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2023.102510_b0520","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed\/Refractory Marginal Zone Lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102510_b0525","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0530","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bjh.15843","article-title":"Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial","volume":"185","author":"Becnel","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2023.102510_b0535","first-page":"3999","article-title":"Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Phase II Study. Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0540","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/bloodadvances.2021006083","article-title":"Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"6","author":"Phillips","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2023.102510_b0545","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1002\/cncr.26627","article-title":"Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study","volume":"118","author":"Wang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2023.102510_b0550","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0555","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.18036","article-title":"Diagnosis and management of Waldenstr\u00f6m macroglobulinaemia\u2014A British Society for Haematology guideline","volume":"197","author":"Pratt","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2023.102510_b0560","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstr\u00f6m macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0565","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstr\u00f6m macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0570","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"NEJM"},{"key":"10.1016\/j.ctrv.2023.102510_b0575","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstr\u00f6m Macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0580","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41375-021-01417-9","article-title":"Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia","volume":"36","author":"Castillo","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2023.102510_b0585","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstr\u00f6m's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0590","doi-asserted-by":"crossref","first-page":"E312","DOI":"10.1002\/ajh.24366","article-title":"Atrial fibrillation associated with ibrutinib in Waldenstr\u00f6m macroglobulinemia","volume":"91","author":"Gustine","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2023.102510_b0595","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","article-title":"Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach","volume":"102","author":"de Weerdt","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2023.102510_b0600","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.25023","article-title":"Ibrutinib discontinuation in Waldenstr\u00f6m macroglobulinemia: Etiologies, outcomes, and IgM rebound","volume":"93","author":"Gustine","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2023.102510_b0605","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0610","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0615","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood-2021-146744","volume":"138","author":"Suzuki","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0620","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-149350","article-title":"Efficacy and Safety of Orelabrutinib in Relapsed\/Refractory Waldenstrom's Macroglobulinemia Patients","volume":"138","author":"Zhou","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0625","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: Drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2023.102510_b0630","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood.2021012953","article-title":"Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstr\u00f6m macroglobulinemia","volume":"138","author":"Treon","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102510_b0635","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in Previously Treated Waldenstr\u00f6m Macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102510_b0640","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/1078-0432.CCR-08-0862","article-title":"Lenalidomide and rituximab in Waldenstrom's macroglobulinemia","volume":"15","author":"Treon","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223000014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223000014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:28:28Z","timestamp":1759656508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737223000014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":128,"alternative-id":["S0305737223000014"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102510","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102510","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102510"}}